ICLR — ICON plc

Is ICLR overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Oversold As of November 17, 2026

ICON plc (ICLR) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $191.40. The rating moved from Strong Oversold to Oversold on November 16, 2026.

See all oversold Healthcare stocks →

AI analysis

ICON plc (ICLR) benefits from a multi-year secular trend toward outsourcing of clinical development, a diversified service mix including high-growth specialty capabilities, and a strong client roster that supports steady contract flow and cash generation. Near-term catalysts include continued R&D spending by large pharma and expansion in specialty trial work; downside is driven by trial timing variability, competitive pricing pressure, and any pullback in sponsor funding. Current market tone is cautious but not volatile, which should allow fundamentals to drive performance over the coming weeks.

Key factors

  • Strong secular demand for outsourced clinical development and increased biopharma R&D budgets supporting long-term revenue visibility
  • Diversified service offering across phases, specialty services (e.g., cell & gene, rare disease) and data/analytics enhances stickiness and upsell potential
  • Scale and established client relationships with large and mid-sized pharma/biotech provide recurring contract flow and pricing leverage
  • Solid cash generation and balance-sheet flexibility to fund investments and selective M&A to extend capabilities
  • Readthrough from large-cap pharma defensive flows that keep investor interest in healthcare and sustain trial pipelines
  • Limited near-term headline risk from filings or social sentiment (recent Form 4 neutral) keeps focus on fundamentals

Risks

  • Clinical trial delays, protocol amendments or site enrollment issues that push revenue recognition and margin realization later
  • Pricing pressure and competitive intensity from other global CROs and niche service providers compressing margins
  • Concentration risk with large clients or programs; loss or slowdown at a major sponsor could materially affect near-term revenues
  • Macro / capital markets weakness reducing biotech funding and delaying sponsor trial starts or expansions
  • Regulatory changes or increased scrutiny of clinical trial operations that raise compliance costs or slow timelines
  • Execution risk on integration of acquisitions or on scaling newer service lines (e.g., cell & gene)

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for ICLR — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.